Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.
Human papillomavirus vaccine can prevent cervical, anal and oral cancers.
The agency hopes to make better use of information from patients and providers.
Where appropriate, the FDA supports broader labeling of companion diagnostics.
The agency clarifies how test developers may use clinical evidence in public databases to show that their test is “clinically valid.”
The life-threatening side effect, called differentiation syndrome, is related to the acute myeloid leukemia medicine Idhifa (enasidenib).
A clinical trial showed that 21 percent of participants achieved complete remission.
Review of evidence indicates Truxima works similarly to Rituxan.
Daurismo (glasdegib) plus chemotherapy improved overall survival in clinical trial.
This is the first FDA approval for treatment of newly diagnosed PTCL; the agency used a new program to complete the approval more quickly.
A non-animal based model could potentially help replace dogs in future trials with new informatics tools.
Patients and providers must have the evidence that they need and deserve to inform effective medical care.
Steps aim to reduce use of electronic nicotine systems and flavored tobacco products by youth.
Changing drug treatment based on results from insufficiently substantiated genetic tests could lead to serious health consequences.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.